Cargando…
Arsenic trioxide inhibits glioma cell growth through induction of telomerase displacement and telomere dysfunction
Glioblastomas are resistant to many kinds of treatment, including chemotherapy, radiation and other adjuvant therapies. As(2)O(3) reportedly induces ROS generation in cells, suggesting it may be able to induce telomerase suppression and telomere dysfunction in glioblastoma cells. We show here that A...
Autores principales: | Cheng, Ye, Li, Yunqian, Ma, Chengyuan, Song, Yang, Xu, Haiyang, Yu, Hongquan, Xu, Songbai, Mu, Qingchun, Li, Haisong, Chen, Yong, Zhao, Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914314/ https://www.ncbi.nlm.nih.gov/pubmed/26871293 http://dx.doi.org/10.18632/oncotarget.7259 |
Ejemplares similares
-
Telomere targeting with a novel G-quadruplex-interactive ligand BRACO-19 induces T-loop disassembly and telomerase displacement in human glioblastoma cells
por: Zhou, Guangtong, et al.
Publicado: (2016) -
Arsenic trioxide as a novel anti-glioma drug: a review
por: Fang, Yi, et al.
Publicado: (2020) -
Telomere and Telomerase Therapeutics in Cancer
por: Xu, Yucheng, et al.
Publicado: (2016) -
Phase I/II trial of local interstitial chemotherapy with arsenic trioxide in patients with newly diagnosed glioma
por: Han, Dayong, et al.
Publicado: (2022) -
Telomeres and telomerase in oncogenesis
por: Trybek, Tomasz, et al.
Publicado: (2020)